openPR Logo
Press release

Severe Hypertriglyceridemia Pipeline Drugs 2024 | Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical,

08-02-2024 11:30 PM CET | Health & Medicine

Press release from: ABNewswire

Severe Hypertriglyceridemia Pipeline Drugs 2024 | Arrowhead

DelveInsight's, "Severe Hypertriglyceridemia Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Severe Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Severe Hypertriglyceridemia Pipeline. Dive into DelveInsight's comprehensive report today! @ Severe Hypertriglyceridemia Pipeline Outlook [https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Severe Hypertriglyceridemia Pipeline Report

* August 2024:- Ionis Pharmaceuticals- An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia (SHTG). This is a multi-center, open-label study of up to 700 participants with SHTG who would be rolled over from studies ISIS 678354-CS5 (NCT05079919) or ISIS 678354-CS6 (NCT05552326). Day 1 of this study may be same as the Week 53 visit of either ISIS 678354-CS5 or ISIS 678354-CS6, as applicable. Participants will receive olezarsen during the 53-week treatment period. The study will include a 31-day qualification Period, a 53-week treatment period, and a 13-week post-treatment period.
* DelveInsight's Severe Hypertriglyceridemia pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Severe Hypertriglyceridemia treatment.
* The leading Severe Hypertriglyceridemia Companies such as Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical, Acasti Pharma Inc., NorthSea Therapeutics, Matinas BioPharma, and others.
* Promising Severe Hypertriglyceridemia Therapies such as Olezarsen, Plozasiran Injection, and others.

Stay ahead with the most recent pipeline outlook for Severe Hypertriglyceridemia. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Severe Hypertriglyceridemia Treatment Drugs [https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Severe Hypertriglyceridemia Emerging Drugs Profile

* ARO-APOC3: Arrowhead Pharmaceuticals

ARO-APOC3 is designed to reduce production of Apolipoprotein C-III (apoC-III), a component of triglyceride rich lipoproteins (TRLs) including VLDL and chylomicrons and is a key regulator of triglyceride metabolism. The company believes that knocking down the hepatic production of apoC-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants. Currently, it is in Phase II stage of clinical trial evaluation to treat Severe Hypertriglyceridemia.

* Olezarsen: Ionis Pharmaceuticals

Olezarsen, formerly known as IONIS-APOCIII-LRx and AKCEA-APOCIII-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to inhibit the production of apoC-III in the liver. ApoC-III is a protein that regulates triglyceride metabolism in the blood by inhibiting lipoprotein lipase that breakdown triglycerides and by preventing clearance of triglyceride-rich lipoproteins. ApoC-III is an independent risk factor for both pancreatitis and cardiovascular disease.

Explore groundbreaking therapies and clinical trials in the Severe Hypertriglyceridemia Pipeline. Access DelveInsight's detailed report now! @ New Severe Hypertriglyceridemia Drugs [https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Severe Hypertriglyceridemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Inhalation
* Inhalation/Intravenous/Oral
* Intranasal
* Intravenous
* Intravenous/ Subcutaneous
* NA
* Oral
* Oral/intranasal/subcutaneous
* Parenteral
* Subcutaneous

Severe Hypertriglyceridemia Products have been categorized under various Molecule types such as

* Antibody
* Antisense oligonucleotides
* Immunotherapy
* Monoclonal antibody
* Peptides
* Protein
* Recombinant protein
* Small molecule
* Stem Cell
* Vaccine

Unveil the future of Severe Hypertriglyceridemia Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Severe Hypertriglyceridemia Market Drivers and Barriers [https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Severe Hypertriglyceridemia Pipeline Report

* Coverage- Global
* Severe Hypertriglyceridemia companies- Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical, Acasti Pharma Inc., NorthSea Therapeutics, Matinas BioPharma, and others.
* Severe Hypertriglyceridemia Therapies such as Olezarsen, Plozasiran Injection, and others.
* Severe Hypertriglyceridemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Severe Hypertriglyceridemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Severe Hypertriglyceridemia Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Severe Hypertriglyceridemia Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Severe Hypertriglyceridemia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Severe Hypertriglyceridemia - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Olezarsen: Ionis Pharmaceuticals
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* ARO-APOC3: Arrowhead Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Severe Hypertriglyceridemia Key Companies
* Severe Hypertriglyceridemia Key Products
* Severe Hypertriglyceridemia- Unmet Needs
* Severe Hypertriglyceridemia- Market Drivers and Barriers
* Severe Hypertriglyceridemia- Future Perspectives and Conclusion
* Severe Hypertriglyceridemia Analyst Views
* Severe Hypertriglyceridemia Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=severe-hypertriglyceridemia-pipeline-drugs-2024-arrowhead-pharmaceuticals-ionis-pharmaceuticals-inc-89bio-inc-regeneron-pharmaceuticals-kowa-research-institute-inc-mochida-pharmaceutical]
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Severe Hypertriglyceridemia Pipeline Drugs 2024 | Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical, here

News-ID: 3609284 • Views:

More Releases from ABNewswire

What are the most effective medical therapies for managing excess body mass? Regenerative Medicine Advances Transform Cape Coral Weight Management Programs
What are the most effective medical therapies for managing excess body mass? Reg …
Cape Coral healthcare providers report breakthrough success using FDA-approved GLP-1 medications for weight management, with Premier Wellness Florida leading comprehensive treatment programs combining pharmaceuticals with holistic wellness support. Cape Coral, FL - Recent clinical developments in medical weight management have prompted Southwest Florida healthcare providers to report significant patient success rates with FDA-approved medications and comprehensive treatment protocols. Premier Wellness Florida, operating from its Del Prado Boulevard facility, has documented patient
Winkler Kurtz LLP - Long Island Lawyers Port Jefferson Station Injury Attorney Offering Trusted Legal Support
Winkler Kurtz LLP - Long Island Lawyers Port Jefferson Station Injury Attorney O …
Winkler Kurtz LLP is a leading Long Island law firm specializing in personal injury cases such as car accidents, slip and falls, and medical malpractice. Offering decades of local experience, the firm provides compassionate support and skilled legal advocacy to help injury victims secure justice and compensation. With free consultations and a contingency fee policy, Winkler Kurtz LLP ensures quality legal help is available to all Long Islanders in need. When
How to Pick the Best Online Chemistry Tutoring Platform
How to Pick the Best Online Chemistry Tutoring Platform
Image: https://www.abnewswire.com/upload/2025/10/814f4b38d9855ce5fcc0509bfebaa240.jpg Choosing the right chemistry tutoring platform can make the difference between academic success and continued struggles with complex reactions and molecular structures. With students increasingly turning to digital solutions for personalized learning support, the online chemistry tutoring market has exploded with options promising everything from AI-powered progress tracking to virtual lab experiences that transform how learners approach this challenging subject. Essential Platform Features for Effective Online Chemistry Tutoring Modern chemistry tutoring
Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight
Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinica …
DelveInsight's "Chronic Myeloid Leukemia Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Chronic Myeloid Leukemia pipeline landscape. It covers the Chronic Myeloid Leukemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Curious

All 5 Releases


More Releases for Severe

Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Clinical Trials, Compan …
DelveInsight's "Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne, historical and forecasted epidemiology as well as the Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. DelveInsight's analysis highlights that several key companies are actively
Severe Combined Immunodeficiency (SCID) Market: A Comprehensive Overview
Severe Combined Immunodeficiency (SCID) is a rare but life-threatening genetic disorder that affects the immune system, leaving individuals vulnerable to infections. It is often referred to as "bubble boy disease," due to its dramatic impact on the immune system, which fails to protect the body from pathogens. SCID can be caused by various mutations in different genes, and it leads to a complete or near-complete absence of functional T-cells and
Severe Breathing Care Ventilator Market Size 2024 to 2031.
Market Overview and Report Coverage The Severe Breathing Care Ventilator Market refers to the market for medical devices that help patients with severe breathing difficulties by providing assistance with their respiration. These ventilators are crucial in treating patients with conditions such as respiratory failure, chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS). The future outlook for the Severe Breathing Care Ventilator Market is very promising, with a
Severe Asthma Treatment Market - Revitalizing Quality of Life: Severe Asthma Tre …
Newark, New Castle, USA: The "Severe Asthma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Severe Asthma Treatment Market: https://www.growthplusreports.com/report/severe-asthma-treatment-market/8939 This latest report researches the industry structure,
Severe Hypertriglyceridemia Market - Breaking Barriers in Managing Cholesterol L …
Newark, New Castle, USA: The "Severe Hypertriglyceridemia Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Severe Hypertriglyceridemia Market: https://www.growthplusreports.com/report/severe-hypertriglyceridemia-market/8763 This latest report researches the industry structure, sales, revenue,
Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017, provides an overview of the Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline landscape. Severe acute respiratory syndrome (SARS) is a serious, potentially